Peter J Castaldi1, Craig P Hersh2, John J Reilly3, Edwin K Silverman4. 1. Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA. 2. Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Electronic address: craig.hersh@channing.harvard.edu. 3. Pulmonary and Critical Care Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. 4. Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Abstract
BACKGROUND: Hypoxemia, hypercarbia, and pulmonary arterial hypertension are known complications of advanced COPD. We sought to identify genetic polymorphisms associated with these traits in a population of patients with severe COPD from the National Emphysema Treatment Trial (NETT). METHODS: In 389 participants from the NETT Genetics Ancillary Study, single-nucleotide polymorphisms (SNPs) were genotyped in five candidate genes previously associated with COPD susceptibility (EPHX1, SERPINE2, SFTPB, TGFB1, and GSTP1). Linear regression models were used to test for associations among these SNPs and three quantitative COPD-related traits (Pao(2), Paco(2), and pulmonary artery systolic pressure). Genes associated with hypoxemia were tested for replication in probands from the Boston Early-Onset COPD Study. RESULTS: In the NETT Genetics Ancillary Study population, SNPs in microsomal epoxide hydrolase (EPHX1) [p = 0.01 to 0.04] and serpin peptidase inhibitor, clade E, member 2 (SERPINE2) [p = 0.04 to 0.008] were associated with hypoxemia. One SNP within surfactant protein B (SFTPB) was associated with pulmonary artery systolic pressure (p = 0.01). In probands from the Boston Early-Onset COPD Study, SNPs in EPHX1 and in SERPINE2 were associated with the requirement for supplemental oxygen. CONCLUSIONS: In participants with severe COPD, SNPs in EPHX1 and SERPINE2 were associated with hypoxemia in two separate study populations, and SNPs from SFTPB were associated with pulmonary artery pressure in the NETT participants.
BACKGROUND:Hypoxemia, hypercarbia, and pulmonary arterial hypertension are known complications of advanced COPD. We sought to identify genetic polymorphisms associated with these traits in a population of patients with severe COPD from the National Emphysema Treatment Trial (NETT). METHODS: In 389 participants from the NETT Genetics Ancillary Study, single-nucleotide polymorphisms (SNPs) were genotyped in five candidate genes previously associated with COPD susceptibility (EPHX1, SERPINE2, SFTPB, TGFB1, and GSTP1). Linear regression models were used to test for associations among these SNPs and three quantitative COPD-related traits (Pao(2), Paco(2), and pulmonary artery systolic pressure). Genes associated with hypoxemia were tested for replication in probands from the Boston Early-Onset COPD Study. RESULTS: In the NETT Genetics Ancillary Study population, SNPs in microsomal epoxide hydrolase (EPHX1) [p = 0.01 to 0.04] and serpin peptidase inhibitor, clade E, member 2 (SERPINE2) [p = 0.04 to 0.008] were associated with hypoxemia. One SNP within surfactant protein B (SFTPB) was associated with pulmonary artery systolic pressure (p = 0.01). In probands from the Boston Early-Onset COPD Study, SNPs in EPHX1 and in SERPINE2 were associated with the requirement for supplemental oxygen. CONCLUSIONS: In participants with severe COPD, SNPs in EPHX1 and SERPINE2 were associated with hypoxemia in two separate study populations, and SNPs from SFTPB were associated with pulmonary artery pressure in the NETT participants.
Authors: Daniel J Schaid; Charles M Rowland; David E Tines; Robert M Jacobson; Gregory A Poland Journal: Am J Hum Genet Date: 2001-12-27 Impact factor: 11.025
Authors: X Guo; H M Lin; Z Lin; M Montaño; R Sansores; G Wang; S DiAngelo; A Pardo; M Selman; J Floros Journal: Eur Respir J Date: 2001-09 Impact factor: 16.671
Authors: Anja Sterner-Kock; Irmgard S Thorey; Katri Koli; Frank Wempe; Jürgen Otte; Thorsten Bangsow; Katharina Kuhlmeier; Thomas Kirchner; Shenchu Jin; Jorma Keski-Oja; Harald von Melchner Journal: Genes Dev Date: 2002-09-01 Impact factor: 11.361
Authors: Edwin K Silverman; Lyle J Palmer; Jonathan D Mosley; Matthew Barth; Jody M Senter; Alison Brown; Jeffrey M Drazen; David J Kwiatkowski; Harold A Chapman; Edward J Campbell; Michael A Province; D C Rao; John J Reilly; Leo C Ginns; Frank E Speizer; Scott T Weiss Journal: Am J Hum Genet Date: 2002-03-25 Impact factor: 11.025
Authors: Kimberly A Smith; Guillaume Voiriot; Haiyang Tang; Dustin R Fraidenburg; Shanshan Song; Hisao Yamamura; Aya Yamamura; Qiang Guo; Jun Wan; Nicole M Pohl; Mohammad Tauseef; Rolf Bodmer; Karen Ocorr; Patricia A Thistlethwaite; Gabriel G Haddad; Frank L Powell; Ayako Makino; Dolly Mehta; Jason X-J Yuan Journal: Am J Respir Cell Mol Biol Date: 2015-09 Impact factor: 6.914
Authors: Janet G Shaw; Annette G Dent; Linda H Passmore; Darryl J Burstow; Rayleen V Bowman; Paul V Zimmerman; Kwun M Fong; Ian A Yang Journal: BMC Pulm Med Date: 2012-06-13 Impact factor: 3.317
Authors: Merry-Lynn N McDonald; Michael H Cho; Inga-Cecilie Sørheim; Sharon M Lutz; Peter J Castaldi; David A Lomas; Harvey O Coxson; Lisa D Edwards; William MacNee; Jørgen Vestbo; Julie C Yates; Alvar Agusti; Peter M A Calverley; Bartolome Celli; Courtney Crim; Stephen I Rennard; Emiel F M Wouters; Per Bakke; Ruth Tal-Singer; Bruce E Miller; Amund Gulsvik; Richard Casaburi; J Michael Wells; Elizabeth A Regan; Barry J Make; John E Hokanson; Christoph Lange; James D Crapo; Terri H Beaty; Edwin K Silverman; Craig P Hersh Journal: Am J Respir Cell Mol Biol Date: 2014-11 Impact factor: 6.914